Catriona M. McNeil

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.7K citations · Full text

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.3K citations · Full text

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter, Antoni Ribas, Georgina V. Long et al. · The Lancet · 2017 · 1.2K citations

Open-label Phase 3, Medicine, Melanoma +8

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology · 2019 · 1.1K citations

Medicine, Melanoma, Immunology +9

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert et al. · The Lancet Oncology · 2017 · 483 citations

Medicine, Melanoma, Ipilimumab 10 +8